In yesterday’s Wall Street session, Pacific Biosciences of California Inc (NASDAQ:PACB) shares traded at $9.79, up 10.50% from the previous session.
PACB stock price is now 25.36% away from the 50-day moving average and -6.33% away from the 200-day moving average. The market capitalization of the company currently stands at $2.62B.
With the price target of $11, Stephens recently initiated with Overweight rating for Pacific Biosciences of California Inc (NASDAQ: PACB).
In other news, Kim Susan G., insider sold 19,257 shares of the company’s stock on Sep 29. The stock was sold for $162,471 at an average price of $8.44. Upon completion of the transaction, the insider now directly owns 306,085 shares in the company, valued at $3.0 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 18, HENRY CHRISTIAN O sold 96,844 shares of the business’s stock. A total of $980,255 was realized by selling the stock at an average price of $10.12. This leaves the insider owning 1,106,095 shares of the company worth $10.83 million. Insiders disposed of 258,239 shares of company stock worth roughly $2.53 million over the past 1 year. A total of 4.13% of the company’s stock is owned by insiders.
During the past 12 months, Pacific Biosciences of California Inc has had a low of $5.74 and a high of $14.55. As of last week, the company has a debt-to-equity ratio of 1.22, a current ratio of 4.80, and a quick ratio of 4.43. The fifty day moving average price for PACB is $7.81 and a two-hundred day moving average price translates $10.45 for the stock.
The latest earnings results from Pacific Biosciences of California Inc (NASDAQ: PACB) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at -$0.26, beating analysts’ expectations of -$0.33 by 0.07. This compares to -$0.34 EPS in the same period last year. The net profit margin was -182.34% and return on equity was -44.46% for PACB. The company reported revenue of $55.69 million for the quarter, compared to $32.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 72.36 percent. For the current quarter, analysts expect PACB to generate $55.72M in revenue.
